Serum haptoglobin and alpha 1-acid glycoprotein as indicators of the effectiveness of cis-diamminedichloroplatinum (CDDP) in ovarian cancer patients--a preliminary report.
Twenty-one patients with adenocarcinoma of the ovary were given a maximum of five courses of CDDP by i.v. infusion every 4 weeks. With one exception, the serum levels of both haptoglobin and alpha 1-acid glycoprotein correlate with tumour burden before therapy and at follow-up. It is suggested that a more accurate assessment of the effectiveness of CDDP therapy may be obtained by estimating these serum proteins before each infusion than by an abdominal examination.
D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006242:Haptoglobins / Q000032:analysis*; D006801:Humans; D008875:Middle Aged; D009961:Orosomucoid / Q000032:analysis*; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy*
D006242:Haptoglobins; D009961:Orosomucoid; D002945:Cisplatin